The European Union has granted Boston Scientific Corp. CE Mark approval to market its Livian heart device, which is designed to treat patients with cardiac failure. The device, which is being evaluated by the U.S. FDA, monitors heartbeats and improves the heart's pumping ability by delivering small electrical impulses.

Related Summaries